NL-OMON47669已完成2 期
A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH. - Irreversible AOC3 inhibitor in NASH.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Clinical evidence of NASH defined as
- •a. histological evidence of NASH (no more than 3 years prior to screening)
- •b. clinical imaging results suggestive of NASH (no more than 3 years prior to screening)
- •i. evidence of hepatic steatosis > 5% measured by the MRI-PDFF protocol ) or assessed as moderate to severe steatosis (raised echogenicity) by ultrasound
- •ii. evidence of liver fibrosis defined as mean stiffness > 3.64 kPa as measured by the MRE protocol or mean stiffness > 7.2 kPa as measured by ultrasound based transient elastography (Fibroscan®);;2. ALT > 1.5 ULN at screening and ALT > 1.25 ULN in a local lab within 1 week to 3 months prior screening;;3. Age * 18 and *75 years at screening;;4. BMI *25kg/m2 and < 45kg/m2 at screening;;5. Stable body weight defined as less than 5% change in body weight in the 3 months prior to screening while being treated with the standard of care site and not treated with anti-obesity medication at screening;;6. Treatment with Antidiabetic concomitant medication including any insulin regimen needs to be stable for 3 months and treatment with vitamin E needs to be stable for 6 months prior to informed consent and expected to be stable throughout the trial. All other concomitant medication has to be stable for at least 4 weeks prior screening. Concomitant medications taken to treat acute conditions (e.g. headache, sinusitis) for a short period (< 7 days) are permissible, if not otherwise prohibited. For restricted medications please refer to section 4.2.2.1;;Further criteria apply, see protocol section 3.3.2.
排除标准
- •1. Current or history of significant alcohol consumption (defined as intake of >210g/week in males and >140g/week in females on average over a consecutive period of more than 3 months) or inability to reliably quantify alcohol consumption based on investigator judgement. ;2. Prior participation in an interventional NASH trial 6 months before baseline or 5 times halflife of the investigational drug, whichever is longer. ;3. Prior or planned bariatric surgery during study conduct, except gastric-band surgery more than 2 years prior to screening (including adjustments) with a stable body weight within the last 12 months. ;4. Use of drugs historically associated with liver injury, hepatic steatosis or steatohepatitis in the 4 weeks prior to screening;5. History of liver cirrhosis (fibrosis stage 4), or hepatic decompensation (e.g. ascites, hepatic encephalopathy, variceal bleeding, etc.) or history of other forms of chronic liver disease (for example Hepatitis B, Hepatitis C, autoimmune liver disease, primary biliary sclerosis, primary sclerosing cholangitis, Wilsons disease, hemochromatosis, A1At deficiency, history of liver transplantation).;6. Active known chronic or relevant acute infections, such as HIV (Human Immunodeficiency Virus), \viral hepatitis, or tuberculosis. QuantiFERON® TB test and HBs Ag test will be performed during screening. Patients with a positive test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active infection.;7. Solid liver lesions other than haemangiomas. a. Suspicion or diagnosis or history of hepatocellular carcinoma (HCC) ;8. eGFR <60ml/min/1.73m2 at screening (CKD-EPI formula). ;9. ALT >5.0 ULN at screening. ;10. Platelet count <150.000/*L ;Further criteria apply, see protocol section 3.3.3.
研究者
相似试验
进行中（未招募）
1 期
BI 425809 in patients with cognitive impairment due to Alzheimer's Disease.EUCTR2015-005438-24-GRBoehringer Ingelheim Ellas AE750
进行中（未招募）
1 期
BI 425809 in patients with cognitive impairment due to Alzheimer's Disease.Cognitive impairment due to Alzheimer's DiseaseMedDRA version: 19.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 19.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005438-24-NOBoehringer Ingelheim Norway KS750
进行中（未招募）
1 期
Alzheimer Disease Proof of Concept Study with BI 409306 versus PlaceboEUCTR2013-005031-24-DEBoehringer Ingelheim Pharma GmbH & Co. KG1,000
进行中（未招募）
1 期
Different doses of BI 1467335 compared to placebo in patients with clinical evidence of NASHEUCTR2016-000499-83-DEBoehringer Ingelheim Pharma GmbH & Co. KG108
进行中（未招募）
1 期
BI 425809 in patients with cognitive impairment due to Alzheimer's Disease.Cognitive impairment due to Alzheimer's DiseasePatients with diagnosis of mild-to moderate Alzheimer's dementia according to teh recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.MedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005438-24-ESBoehringer Ingelheim España, S.A.950